Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06398457 | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | recruiting | Early Phase 1 | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07059975 | UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML | recruiting | Early Phase 1 | 36 | Baylor College of MedicineOTHER |
| 1 |
| Aug 24, 2026 |
| clinicaltrials |
| NCT07771803 | A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)(Soursop) | recruiting | Early Phase 1 | 20 | Roger StrairOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03964506 | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | recruiting | Early Phase 1 | 24 | Omar AljitawiOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07071155 | Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia(M-HArbOr) | recruiting | Early Phase 1 | 18 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07144020 | Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia | recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07126782 | The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT | recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06980155 | XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia | recruiting | Early Phase 1 | 60 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06201247 | Off-the-shelf CD123 CAR-NK for R/R AML | recruiting | Early Phase 1 | 12 | Peking University People's HospitalOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06760260 | Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 7 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06762132 | A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 27 | Zhejiang UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06642025 | EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 9 | Zhimin ZhaiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04662294 | CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases | recruiting | Early Phase 1 | 108 | Zhejiang UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials